Avalo Therapeutics, Inc. Common Stock (AVTX) is a publicly traded Healthcare sector company. As of July 28, 2026, AVTX trades at $19.27 with a market cap of $975.53M and a P/E ratio of -3.39. AVTX moved +0.00% today. Year to date, AVTX is +7.38%; over the trailing twelve months it is +191.48%. Its 52-week range spans $3.39 to $24.27. Analyst consensus is strong buy with an average price target of $44.90. Rallies surfaces AVTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for AVTX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $19.27 |
| Market Cap | $975.53M |
| P/E Ratio | -3.39 |
| EPS | $-5.84 |
| Dividend Yield | 0.00% |
| 52-Week High | $24.27 |
| 52-Week Low | $3.39 |
| Volume | 23.48K |
| Avg Volume | 0 |
| Revenue (TTM) | $59.00K |
| Net Income | $-78.26M |
| Gross Margin | 0.00% |
11 analysts cover AVTX: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.90.